Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis.

Farida AhangariChristine BeckerDaniel G FosterMaurizio ChioccioliMeghan NelsonKeriann BekeXing WangAurelien JustetTaylor AdamsBenjamin ReadheadCarly MeadorKelly CorrellLoukia N LiliHelen M RoybalKadi-Ann RoseShuizi DingThomas BarnthalerNatalie BrionesGiuseppe DeIuliisJonas Christian SchuppQin LiNorihito OmoteYael AschnerLokesh SharmaKatrina W KopfBjörn MagnussonRyan HicksAnna BackmarkCharles S Dela CruzIvan RosasLeslie P CousensJoel T DudleyNaftali KaminskiGregory P Downey

Published in: American journal of respiratory and critical care medicine (2022)

These studies identify novel Src-dependent fibrogenic pathways and support the study of the therapeutic effectiveness of saracatinib in IPF treatment.

Keyphrases

pulmonary fibrosis
idiopathic pulmonary fibrosis
tyrosine kinase
randomized controlled trial
systematic review
systemic sclerosis
stem cells
cell therapy